Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Solasia Pharma KK ( (JP:4597) ) just unveiled an update.
Solasia Pharma K.K. has entered a licensing agreement with Firebird Biologics for the exclusive sales and distribution of DARVIAS and episil across 19 countries in Southeast Asia, Oceania, the Middle East, and Africa. This agreement marks a significant step in Solasia’s expansion strategy, with Firebird Biologics also obtaining sales approval for episil in Singapore, initiating preparations for sales activities, and beginning product supply from Solasia.
More about Solasia Pharma KK
Solasia Pharma K.K. operates in the pharmaceutical industry, focusing on the development and commercialization of oncology drugs and medical devices. The company is headquartered in Tokyo, Japan, and is known for products like the antitumor drug DARVIAS and the medical device episil, which is used for managing oral pain caused by cancer treatments.
Average Trading Volume: 13,641,941
Technical Sentiment Signal: Buy
Current Market Cap: Yen9.97B
For detailed information about 4597 stock, go to TipRanks’ Stock Analysis page.